Development of new treatment for chondrosarcoma by targeting sarcoma stem cells

• Project/Area Number: 23592192
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Orthopaedic surgery
• Research Institution: Kyushu University
• Principal Investigator: MATSUMOTO Yoshihiro 九州大学, 大学病院, 助教 (10346794)
• Co-Investigator(Kenkyū-buntansha): MATSUMOTO Kazu 岐阜大学, 医学部附属病院, 講師 (40422711)
• Project Period (FY): 2011-04-28 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000); Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
• Keywords: 軟骨肉腫 / 肉腫幹細胞 / 骨軟部腫瘍 / 薬剤耐性 / 癌幹細胞 / 悪性骨軟部腫瘍 / 腫瘍幹細胞

Outline of Final Research Achievements

Primary chondrosarcoma (CS) is the second most common primary malignant tumor of bone. Despite the continuous development and progress made in diagnostic techniques and auxiliary treatment, there is still no good treatment for CS at present. To develop new treatment for CS, we studied the oncogenesis of CS by focusing on the CS stem cells. We found that S100A4 and type I collgen were expressed in CS cell line that would have phenotype of CS stem cell by spheroid colony assay. We also established drug-resistance CS cell lines and the cell line expressed P-glycoprotein (Pgp), indicating that Pgp was able to be a candidate of molecular target of CS treatment.

Research Products

• [Journal Article] Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways. (2015)
  • Author(s): Nabeshima Y., Matsumoto Y., Iwamoto Y., et al
  • Journal Title: British Journal of Cancer Volume: NA Pages: 547-55
  • DOI: 10.1038/bjc.2014.637
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Malignant peripheral nerve sheath tumors presenting as spinal dumbbell tumors: clinical outcomes and characteristic imaging features (2014)
  • Author(s): Yoshihiro Matsumoto ; Makoto Endo ; Katsumi Harimaya ; Mitsumasa Hayashida ; Toshio Doi ; Yukihide Iwamoto
  • Journal Title: Eur Spine J Volume: NA Pages: 1-7
  • DOI: 10.1007/s00586-014-3467-8
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Dedifferentiated chondrosarcoma of the cervical spine (2013)
  • Author(s): Matsumoto Y, Takahashi Y, Harimaya K, Nakagawa T, Kawaguchi K, Okada S, Hayashida M, Doi T, Sakamoto A, Matsunobu T, Oda Y, Iwamoto Y
  • Journal Title: World J Surg Oncol. Volume: 2 Pages: 32-32
  • DOI: 10.1186/1477-7819-11-32
  • Peer Reviewed
• [Journal Article] Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma (2013)
  • Author(s): Fujiwara-Okada Y, Matsumoto Y, Fukushi J, Setsu N, Matsuura S, Kamura S, Fujiwara T, Iida K, Hatano M, Nabeshima A, Yamada H, Ono M, Oda Y, Iwamoto Y.
  • Journal Title: Br J Cancer Volume: 108 Pages: 836-847
  • DOI: 10.1038/bjc.2012.579
  • Peer Reviewed
• [Journal Article] miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor (2013)
  • Author(s): Iida K
  • Journal Title: Cancer Cell Int Volume: 13 Pages: 21-21
  • DOI: 10.1186/1475-2867-13-21
  • Peer Reviewed
• [Journal Article] Clinical outcome for patients with dedifferentiated chondrosarcoma : a report of g cases at a single institute. (2012)
  • Author(s): Yokota K, Sakamoto A, Matsumoto Y, Matsuda S, Harimaya K, Oda Y, Iwamoto Y
  • Journal Title: J Orthop Surg Res Volume: 7 Pages: 38-38
  • DOI: 10.1186/1749-799x-7-38
  • Peer Reviewed
• [Journal Article] Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing Family Tumors. (2012)
  • Author(s): Li Y, Li X, Fan G, Fukushi J, Matsumoto Y, Iwamoto Y, Zhu Y.
  • Journal Title: Cancer Lett. Volume: 320 Pages: 14-22
  • Peer Reviewed